↑ 疾患リストへ ← 戻る

 124. 皮質下梗塞と白質脳症を伴う常染色体優性脳動脈症 [臨床試験数:2,薬物数:7(DrugBank:2),標的遺伝子数:1,標的パスウェイ数:2] 

Searched query = "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy", "Autosomal dominant cerebral artery disease with subcortical infarct and leukoencephalopathy", "Autosomal dominant cerebral artery disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-004370-55-IT14/12/200719 March 2012Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial - CADASIL BH4Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial - CADASIL BH4CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), is a rare autosomal dominant disorder characterized by recurrent strokes starting in mid-adulthood and leading in some to severe motor disability with pseudobulbar palsy and dementia of the subcortical type
MedDRA version: 9.1 Level: HLGT Classification code 10008804 Term: Chromosomal abnormalities and abnormal gene carriers
Product Name: Phenoptin
Product Code: 6R-BH4
Pharmaceutical Form: Oral powder
INN or Proposed INN: sapropterin
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Oral powder
Route of administration of the placebo: Oral use
AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)Not RecruitingFemale: yes
Male: yes
Italy
2EUCTR2004-001162-40-FI08/03/200511 December 2017An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASILAn 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASILCerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.
MedDRA version: 7.0 Level: PT Classification code 10057678
Trade Name: Aricept
Product Name: Aricept
Product Code: E2020
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: donepezil hydrochloride
CAS Number: 120011-70-3
Current Sponsor code: E2020
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Eisai LtdNot RecruitingFemale: yes
Male: yes
150Phase 2Finland;Spain;Germany;Italy;United Kingdom;Sweden